PharmaResearch Statistics

Total Valuation

PharmaResearch has a market cap or net worth of KRW 2.16 trillion. The enterprise value is 2.01 trillion.

Market Cap	2.16T
Enterprise Value	2.01T

Important Dates

The last earnings date was Tuesday, November 12, 2024.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

PharmaResearch has 10.39 million shares outstanding. The number of shares has increased by 6.77% in one year.

Current Share Class	n/a
Shares Outstanding	10.39M
Shares Change (YoY)	+6.77%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	38.61%
Owned by Institutions (%)	22.21%
Float	5.20M

Valuation Ratios

The trailing PE ratio is 25.07 and the forward PE ratio is 17.33. PharmaResearch's PEG ratio is 0.60.

PE Ratio	25.07
Forward PE	17.33
PS Ratio	7.14
PB Ratio	4.44
P/TBV Ratio	n/a
P/FCF Ratio	27.22
P/OCF Ratio	n/a
PEG Ratio	0.60

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.18, with an EV/FCF ratio of 25.42.

EV / Earnings	22.19
EV / Sales	6.79
EV / EBITDA	16.18
EV / EBIT	17.99
EV / FCF	25.42

Financial Position

The company has a current ratio of 3.68, with a Debt / Equity ratio of 0.07.

Current Ratio	3.68
Quick Ratio	2.85
Debt / Equity	0.07
Debt / EBITDA	0.30
Debt / FCF	0.44
Interest Coverage	78.52

Financial Efficiency

Return on equity (ROE) is 19.64% and return on invested capital (ROIC) is 13.02%.

Return on Equity (ROE)	19.64%
Return on Assets (ROA)	11.91%
Return on Capital (ROIC)	13.02%
Revenue Per Employee	735.96M
Profits Per Employee	225.17M
Employee Count	403
Asset Turnover	0.54
Inventory Turnover	1.81

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +84.34% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+84.34%
50-Day Moving Average	208,174.00
200-Day Moving Average	147,902.50
Relative Strength Index (RSI)	50.61
Average Volume (20 Days)	148,680

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, PharmaResearch had revenue of KRW 296.59 billion and earned 90.74 billion in profits. Earnings per share was 8,276.27.

Revenue	296.59B
Gross Profit	211.00B
Operating Income	105.30B
Pretax Income	115.82B
Net Income	90.74B
EBITDA	117.81B
EBIT	105.30B
Earnings Per Share (EPS)	8,276.27

Full Income Statement

Balance Sheet

The company has 206.07 billion in cash and 35.05 billion in debt, giving a net cash position of 171.02 billion or 16,460.79 per share.

Cash & Cash Equivalents	206.07B
Total Debt	35.05B
Net Cash	171.02B
Net Cash Per Share	16,460.79
Equity (Book Value)	509.11B
Book Value Per Share	46,706.30
Working Capital	227.30B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 104.28 billion and capital expenditures -25.08 billion, giving a free cash flow of 79.20 billion.

Operating Cash Flow	104.28B
Capital Expenditures	-25.08B
Free Cash Flow	79.20B
FCF Per Share	7,622.66

Full Cash Flow Statement

Margins

Gross margin is 71.14%, with operating and profit margins of 35.50% and 30.60%.

Gross Margin	71.14%
Operating Margin	35.50%
Pretax Margin	39.05%
Profit Margin	30.60%
EBITDA Margin	39.72%
EBIT Margin	35.50%
FCF Margin	26.70%

Dividends & Yields

This stock pays an annual dividend of 950.00, which amounts to a dividend yield of 0.43%.

Dividend Per Share	950.00
Dividend Yield	0.43%
Dividend Growth (YoY)	43.94%
Years of Dividend Growth	4
Payout Ratio	11.54%
Buyback Yield	-6.77%
Shareholder Yield	-6.33%
Earnings Yield	3.99%
FCF Yield	3.67%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

PharmaResearch has an Altman Z-Score of 10.15.

Altman Z-Score	10.15
Piotroski F-Score	n/a